Loading...
Amyloid positron emission tomography (PET) using [18F]-florbetapir can be a biomarker for Alzheimer disease (AD). In this open-label, multicenter study, dementia experts from 18 northern Italian centers diagnosed patients with AD or non-AD after a comprehensive evaluation, rated their diagnostic confidence on a 0–100 scale, and determined whether to start cognitive medications prior to amyloid imaging. After patients underwent amyloid imaging, experts were informed of the results and reassessed their diagnoses, diagnostic confidence, and treatment plan.
Among 228 study participants, experts diagnosed 165 AD patients with a diagnostic confidence of 71% and 63 non-AD patients with a diagnostic confidence of 30%. Mild cognitive impairment was d…